The FY2025 (Dec) proxy of Repligen names 16 peer companies for pay. Among Repligen and these peers, CEO pay was 6th highest of 7 and total shareholder return was 6th highest of 7.
6th highest of 7in Repligen and its pay peers, FY2025 (Dec) by CEO pay:
$4.7M$23.2M
6th highest of 7in Repligen and its pay peers, FY2025 (Dec) by total shareholder return:
$79$403
Pay peer group, FY2025 (Dec) proxy
| Halozyme Therapeutics | ||
| Insulet | ||
| Natera | ||
| Medpace Holdings | ||
| BIO-TECHNE | ||
| Bruker | ||
| 10x Genomics, Inc. | Not disclosed | Not disclosed |
| Azenta, Inc. | Not disclosed | Not disclosed |
| Bio-Rad Laboratories, Inc. | Not disclosed | Not disclosed |
| Maravai LifeSciences Holdings, Inc. | Not disclosed | Not disclosed |
| Mesa Laboratories, Inc. | Not disclosed | Not disclosed |
| NeoGenomics, Inc | Not disclosed | Not disclosed |
| Neogen Corporation | Not disclosed | Not disclosed |
| NovaCure Limited, Inc. | Not disclosed | Not disclosed |
| Quanterix Corporation | Not disclosed | Not disclosed |
| Waters Corporation | Not disclosed | Not disclosed |
16 companies
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| Russell 1000 Index (index) | Not disclosed | Not disclosed |
1 company
Changes by year
FY2025 (Dec) proxy
- RemovedAvid Bioservices, Inc.pay peer group
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.